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most lethal. Injuries from handguns can have extreme clinical
and substantial economic consequences, as well as social 
implications.
HEALTH POLICY
HEALTH POLICY—Burden Of Illness Studies
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OBJECTIVES: This study compares the treatment patterns,
medical characteristics, and average annual direct (i.e., medical
and drug use) and indirect (i.e., work-loss) costs for employees
with Cancer, Back/Neck Disorders, Arthritis, and Neuropathic
Pain (“painful conditions”) to those of employees from a 
random sample (“average employee”) in 2000. METHODS: 
An employer administrative claims database (covering several
managed care health plans and approximately 600,000 insured
lives from 1998–2001) was used to identify patients with ICD-
9 codes for painful conditions. Of these: 3277; 18,657; 22,313;
and 4436 employees between the ages of 18 and 65 were iden-
tiﬁed as having Cancer, Back/Neck Disorders, Arthritis and 
Neuropathic Pain, respectively. Direct costs are total medical and
drug costs paid by the employer, and indirect costs are payments
by the employer during work-loss days. RESULTS: Painful con-
ditions lead to signiﬁcant employer costs. In particular, among
employees with painful conditions, direct costs are 1.5–4.1 times
as high as those of the average employee (i.e., $3961–$11,089
compared to $2686) depending on the painful condition. Indi-
rect costs account for up to 35–45 percent of total employer
costs. Indirect costs are 1.5–2.7 times as high as those of 
the average employee (i.e., $3132–$5870 compared to $2167)
depending on the painful condition. Employees with cancer have
the highest costs among patients with painful conditions. Drug
costs account for approximately 20 percent of direct costs, with
opioids accounting for less than one percent of overall direct
costs. CONCLUSIONS: Painful conditions are costly to employ-
ers, with indirect costs accounting for up to 45 percent of overall
costs. However, prescription opioids used to treat painful con-
ditions account for a small fraction of the costs.
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OBJECTIVE: The effects of work-related stress are generally
judged to be detrimental to workers’ health and costly for
society. The purpose of this study is to set out an evaluation of
the costs of work-related stress for France. METHODS: Occu-
pational stress is deﬁned according to Karasek and Theorell’s
model. Illnesses included in the study are cardiovascular diseases,
depression, musculoskeletal diseases and lower back pain. The
model resorts to the principle of attributable fractions, which 
is based on two parameters, 1) prevalence of exposure to oc-
cupational stress, (2) relative risk to develop an illness as a 
consequence of occupational stress. The valuation of these two
parameters is based on a systematic review of scientiﬁc literature
(epidemiological studies). Cost estimates include medical costs,
cost of absence from work, loss of potential output because of
years of activity lost before retirement age and a valuation of
years of life lost attributable to occupational stress (per capita
GDP). Cost estimates are based on national statistical reports
and reported in 2000 Euros (€). RESULTS: The sensitivity analy-
sis shows that from 220,500 to nearly 335,000 persons (from
1% to 1.4% of working population) were affected by illnesses
attributable to work-related stress and from 1600 to nearly 3000
people died as a result of their illness. As for the diseases con-
sidered here, work-related stress costs society from 830€ million
to 1656€ million in France, which represents from 0.06% to
0.12% of GDP, and from 10.3% to 20.5% of the total spend-
ing of social security work injuries branch. CONCLUSIONS:
These results reﬂect a certain proportion of total economic and
human burden of occupational stress. The study underlines the
necessity of convergent epidemiological studies capable of deter-
mining as reliably as possible the value of relative risk for the 
illnesses.
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OBJECTIVE: Among OECD countries, Korea is of the highest
percentage of males aged 15 and over that are daily smokers.
This study aims to estimate the socioeconomic cost of diseases
due to smoking and to compare with that of all and smoking-
related diseases in Korea. METHODS: This study employs a
prevalence-based approach. First, we estimate both direct and
indirect costs of smoking-related diseases, which are selected
from reviewing existing studies. Direct costs include medical care
expenditures, trafﬁc costs, and caregiver’s costs. Indirect costs
are estimated based on human capital theory. Next, we compute
population attributable risks (PARs) caused by smoking by
disease, age and sex. The socioeconomic costs of diseases due to
smoking are obtained by multiplying the costs of smoking-
related diseases by PARs. We report the estimates at 40 ~ 69 age
group in USA Purchasing Power Parity Dollars. The major data
sources are National Health Insurance Statistical Yearbook,
Annual Report on the Cause of Death Statistics, Survey Report
on Wage Structure, National Health and Nutrition Survey, the
Korean Statistical Information System, and information such as
a report from CDC in U.S.A. RESULTS: The estimated economic
cost of diseases due to smoking in Korea in 2001 is 3.92 billion
USA PPP$($ hereafter) at 0% discount rate, which accounts for
13.8 % of the cost of all diseases and 42.8% of smoking-related
diseases at aged 40 ~ 69. The costs of males and females are
$3.72 billion and 0$.20 billion, respectively. The cost of malig-
nant neoplasms caused by smoking is $1.86 billion (42.3% of
the cost of the diseases), cardiovascular disease, $1.55 billion
(41.0%); respiratory disease, $0.51 billion (16.6%). CONCLU-
SIONS: The economic burden of diseases due to smoking is
about 52.8% (9.5%) of that of smoking related diseases and
18.8% (2.3%) of all diseases in males (females).
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OBJECTIVE: Korea has been facing various public health prob-
lems such as increase in prevalence population ratio and rapid
growth of health expenditures. The aim of the study is to esti-
mate the annual socioeconomic cost of diseases in Korea.
METHODS: We estimate both direct and indirect costs of dis-
eases in Korea in 2001 using a prevalence-based approach.
